WO1998029110A3 - Formulation and method for treating neoplasms by inhalation - Google Patents

Formulation and method for treating neoplasms by inhalation Download PDF

Info

Publication number
WO1998029110A3
WO1998029110A3 PCT/US1997/024289 US9724289W WO9829110A3 WO 1998029110 A3 WO1998029110 A3 WO 1998029110A3 US 9724289 W US9724289 W US 9724289W WO 9829110 A3 WO9829110 A3 WO 9829110A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhalation
formulation
treating neoplasms
composition
neoplasms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/024289
Other languages
French (fr)
Other versions
WO1998029110A2 (en
Inventor
Michael E Placke
Anthony R Imondi
Michael J Brooker
John E Frye
Praful K Shah
Douglas R Flanagan Jr
Maureen D Donovan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Battelle Memorial Institute Inc
Original Assignee
Battelle Memorial Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Battelle Memorial Institute Inc filed Critical Battelle Memorial Institute Inc
Priority to NZ336381A priority Critical patent/NZ336381A/en
Priority to JP53035898A priority patent/JP2001513078A/en
Priority to DE69737510T priority patent/DE69737510T2/en
Priority to CA002275889A priority patent/CA2275889C/en
Priority to AU70975/98A priority patent/AU741439B2/en
Priority to BR9713661-1A priority patent/BR9713661A/en
Priority to EP97955033A priority patent/EP0954283B1/en
Publication of WO1998029110A2 publication Critical patent/WO1998029110A2/en
Publication of WO1998029110A3 publication Critical patent/WO1998029110A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A formulation, method, and apparatus for treating neoplasms such as cancer by administering a pharmaceutically effective amount of highly toxic composition by inhalation, wherein the composition is a non-encapsulated antineoplastic drug.
PCT/US1997/024289 1996-12-30 1997-12-30 Formulation and method for treating neoplasms by inhalation Ceased WO1998029110A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
NZ336381A NZ336381A (en) 1996-12-30 1997-12-30 Formulation and method for treating neoplasms by inhalation
JP53035898A JP2001513078A (en) 1996-12-30 1997-12-30 Formulations and methods for treating neoplasms by inhalation
DE69737510T DE69737510T2 (en) 1996-12-30 1997-12-30 Use of an unencapsulated anticancer drug for the preparation of a preparation for the treatment of neoplasms by inhalation
CA002275889A CA2275889C (en) 1996-12-30 1997-12-30 Formulation and method for treating neoplasms by inhalation
AU70975/98A AU741439B2 (en) 1996-12-30 1997-12-30 Formulation and method for treating neoplasms by inhalation
BR9713661-1A BR9713661A (en) 1996-12-30 1997-12-30 Formulation and method for the treatment of neoplasms by inhalation
EP97955033A EP0954283B1 (en) 1996-12-30 1997-12-30 Use of a non-encapsulated anticancer drug for the preparation of a formulation for treating neoplasms by inhalation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3378996P 1996-12-30 1996-12-30
US60/033,789 1996-12-30

Publications (2)

Publication Number Publication Date
WO1998029110A2 WO1998029110A2 (en) 1998-07-09
WO1998029110A3 true WO1998029110A3 (en) 1999-04-15

Family

ID=21872447

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/024289 Ceased WO1998029110A2 (en) 1996-12-30 1997-12-30 Formulation and method for treating neoplasms by inhalation

Country Status (12)

Country Link
US (5) US6471943B1 (en)
EP (1) EP0954283B1 (en)
JP (1) JP2001513078A (en)
CN (1) CN1245423A (en)
AT (1) ATE357214T1 (en)
AU (1) AU741439B2 (en)
BR (1) BR9713661A (en)
CA (2) CA2275889C (en)
DE (1) DE69737510T2 (en)
ES (1) ES2285743T3 (en)
NZ (1) NZ336381A (en)
WO (1) WO1998029110A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7537009B2 (en) 2001-06-05 2009-05-26 Alexza Pharmaceuticals, Inc. Method of forming an aerosol for inhalation delivery
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US7581540B2 (en) 2004-08-12 2009-09-01 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US8991387B2 (en) 2003-05-21 2015-03-31 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
US9211382B2 (en) 2001-05-24 2015-12-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451784B1 (en) * 1996-12-30 2002-09-17 Battellepharma, Inc. Formulation and method for treating neoplasms by inhalation
AU1200100A (en) * 1998-10-02 2000-04-26 Battelle Memorial Institute Inhalation chemotherapy for prevention and treatment of metastatic tumors in thelung
AU2986800A (en) * 1999-02-08 2000-08-25 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods of inhibiting the hgf-met-upa-plasmin network
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
GB9920548D0 (en) * 1999-08-31 1999-11-03 Rhone Poulenc Rorer Sa Treatment of hepatocellular carcinoma
US6651655B1 (en) * 2000-01-18 2003-11-25 Quadrant Technologies Limited Inhaled vaccines
DE60138535D1 (en) 2000-02-04 2009-06-10 Children S Hospital Res Founda USE OF LYSOSOMAL ACID LIPASE FOR THE TREATMENT OF ATHEROSCLEROSIS AND SIMILAR DISEASES
AU2001244391B9 (en) * 2000-04-03 2006-10-05 Ventaira Pharmaceuticals, Inc. Devices and formulations
US20100282634A1 (en) * 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
US8071740B2 (en) * 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20070286845A1 (en) * 2000-11-17 2007-12-13 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US8039261B2 (en) * 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US6838452B2 (en) * 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
EP1343521A2 (en) * 2000-12-01 2003-09-17 Battelle Memorial Institute Method for the stabilizing biomolecules (e.g. insulin) in liquid formulations
CA2445985A1 (en) * 2001-05-04 2002-11-14 University Of Utah Research Foundation Hyaluronic acid containing bioconjugates: targeted delivery of anti-cancer drugs to cancer cells
CA2457148A1 (en) * 2001-08-20 2003-02-27 Transave, Inc. Treatment of cancers by inhalation of stable platinum-containing formulations
JP2005502653A (en) * 2001-08-20 2005-01-27 トランセーヴ・インコーポレーテッド How to treat lung cancer
WO2003032906A2 (en) * 2001-10-15 2003-04-24 Crititech, Inc. Delivery of poorly soluble drugs
EP1436313B1 (en) * 2001-10-19 2010-09-22 Vascular Biogenics Ltd. Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
US7465718B2 (en) * 2002-02-08 2008-12-16 Conforma Therapeutics Corporation Ansamycins having improved pharmacological and biological properties
AU2003230600B2 (en) * 2002-03-05 2009-06-04 Transave, Inc. An inhalation system for prevention and treatment of intracellular infections
ITPI20020018A1 (en) * 2002-03-28 2002-06-26 Azienda Ospedaliera Pisana FLOW VARIATION PULMONARY VENTILATION
GB0208516D0 (en) * 2002-04-15 2002-05-22 Univ Liverpool Chemotherapy
US20050169883A1 (en) * 2002-05-06 2005-08-04 Prestwich Glenn D. Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents
US7677411B2 (en) * 2002-05-10 2010-03-16 Oriel Therapeutics, Inc. Apparatus, systems and related methods for processing, dispensing and/or evaluatingl dry powders
US6889690B2 (en) * 2002-05-10 2005-05-10 Oriel Therapeutics, Inc. Dry powder inhalers, related blister devices, and associated methods of dispensing dry powder substances and fabricating blister packages
US7118010B2 (en) 2002-05-10 2006-10-10 Oriel Therapeutics, Inc. Apparatus, systems and related methods for dispensing and /or evaluating dry powders
US6985798B2 (en) 2002-05-10 2006-01-10 Oriel Therapeutics, Inc. Dry powder dose filling systems and related methods
AU2003251760A1 (en) * 2002-06-27 2004-01-19 Oriel Therapeutics, Inc. Apparatus and methods for dispensing dry powders
US9186322B2 (en) 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
WO2004054499A2 (en) * 2002-08-02 2004-07-01 Transave, Inc. Platinum aggregates and process for producing the same
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
AU2003304204B2 (en) * 2002-10-29 2009-12-24 Insmed Incorporated Sustained release of antiinfectives
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
US20060179491A1 (en) * 2002-11-12 2006-08-10 Brian Graham Process for treating non-human animals
US7353533B2 (en) 2002-12-18 2008-04-01 Novell, Inc. Administration of protection of data accessible by a mobile device
US7185650B2 (en) * 2002-12-19 2007-03-06 Arie Huber Systems and methods for determining a minimum effective dose of an inhaled drug for an individual patient at a given time
US20060148776A1 (en) * 2003-03-13 2006-07-06 Conforma Therapeutics Corporation Drug formulations having long and medium chain triglycerides
US20040187864A1 (en) * 2003-03-24 2004-09-30 Cindet, Llc Inhalation device and method
DE602004027824D1 (en) * 2003-09-25 2010-08-05 Astellas Pharma Inc ANTITUMORAL AGENT WITH A HISTON DEACETYLASE INHIBITOR AND A TOPOISOMERASE II HEMMER
US7451761B2 (en) * 2003-10-27 2008-11-18 Oriel Therapeutics, Inc. Dry powder inhalers, related blister package indexing and opening mechanisms, and associated methods of dispensing dry powder substances
US7377277B2 (en) * 2003-10-27 2008-05-27 Oriel Therapeutics, Inc. Blister packages with frames and associated methods of fabricating dry powder drug containment systems
AU2005223654A1 (en) * 2004-03-18 2005-09-29 Transave, Inc. Administration of cisplatin by inhalation
AU2005245018A1 (en) * 2004-05-21 2005-12-01 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
US20060045849A1 (en) * 2004-08-24 2006-03-02 Farhan Taghizadeh Method of customizing the fragrance of nasal medications
KR20070089693A (en) * 2004-11-08 2007-08-31 트랜세이브, 인코포레이티드 Method of treating cancer by intraperitoneal administration of a lipid-based platinum compound formulation
EP1871361A2 (en) * 2005-04-07 2008-01-02 Conforma Therapeutics Corporation Phospholipid-based pharmaceutical formulations and methods for producing and using same
US20060283742A1 (en) * 2005-06-16 2006-12-21 Canel Lightning Co. Ltd. Multi-lamp display packaging for lamps with collapsible lampshades
US20090180964A1 (en) * 2005-06-24 2009-07-16 Rao Papineni Transmucosal delivery of optical, spect, multimodal,drug or biological cargo laden nanoparticle(s) in small animals or humans
US20070190182A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007056236A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007056263A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
US20070122350A1 (en) * 2005-11-30 2007-05-31 Transave, Inc. Safe and effective methods of administering therapeutic agents
CN101360492A (en) * 2005-12-01 2009-02-04 康福玛医药公司 Compositions containing ansamycin
ES2798263T3 (en) 2005-12-08 2020-12-10 Insmed Inc Lipid-based compositions of anti-infectives for treating lung infections
GB0526552D0 (en) * 2005-12-29 2006-02-08 Morvus Technology Ltd New use
US20080045589A1 (en) * 2006-05-26 2008-02-21 Susan Kelley Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer
CA2678093C (en) 2007-02-26 2017-10-24 Jon Lundberg Performance enhancing composition and use thereof
US11759477B2 (en) 2007-02-26 2023-09-19 Heartbeet Ltd. Compositions of nitrates and methods of use thereof
US10842813B2 (en) 2007-02-26 2020-11-24 Heartbeet Ltd Compositions of nitrates and methods of use thereof
US10821132B2 (en) 2007-02-26 2020-11-03 Heartbeet Ltd Compositions of nitrates and methods of use thereof
ES2594867T3 (en) 2007-03-09 2016-12-23 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
WO2008134630A1 (en) * 2007-04-30 2008-11-06 Apt Pharmaceuticals Dexrazoxane compounds for cardioprotection
US20080275036A1 (en) * 2007-05-02 2008-11-06 Apt Pharmaceuticals, Inc. Prevention and treatment of cardiac conditions
WO2008137717A1 (en) 2007-05-04 2008-11-13 Transave, Inc. Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
EP2534957B1 (en) 2007-12-14 2015-05-27 AeroDesigns, Inc Delivering aerosolizable products
WO2010042638A2 (en) * 2008-10-07 2010-04-15 Young Bok Lee Hpma - docetaxel or gemcitabine conjugates and uses therefore
CN104587484A (en) 2009-10-13 2015-05-06 瑞沙恩医药公司 Polymeric systems for the delivery of anticancer drugs
PL2852391T3 (en) 2012-05-21 2022-04-11 Insmed Incorporated Systems for the treatment of lung infections
EP2892524B1 (en) 2012-09-04 2020-11-25 Eleison Pharmaceuticals, LLC Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
WO2014081887A1 (en) 2012-11-20 2014-05-30 Spectrum Pharmaceuticals Improved method for the preparation of liposome encapsulated vincristine for therapeutic use
CA2891487A1 (en) 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations
JP6433913B2 (en) * 2012-12-13 2018-12-05 サイトレックス コーポレイション Anthracycline preparation
WO2014197569A1 (en) 2013-06-05 2014-12-11 Cytrx Corporation Cytotoxic agents for the treatment of cancer
WO2015017803A1 (en) * 2013-08-02 2015-02-05 Children's Hospital Medical Center Compositions and methods for treating disease states associated with activated t cells and/or b cells
CN106061482A (en) 2013-10-08 2016-10-26 拉姆医疗公司 Rapamycin for the treatment of lymphangioleiomyomatosis
RU2016136348A (en) 2014-02-11 2018-03-16 Лэм Терапьютикс, Инк. RAPAMYCIN FOR TREATMENT OF LYMPHNANGIOLEIOMYOMATOSIS
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
NZ724756A (en) 2014-04-04 2023-07-28 Ai Therapeutics Inc An inhalable rapamycin formulation for treating age-related conditions
TWI601542B (en) 2014-04-18 2017-10-11 林信湧 Inhalation-type pharmaceutical composition for lung cancer and preparation method thereof
MX384843B (en) 2014-05-15 2025-03-14 Insmed Inc METHODS FOR TREATING NON-TUBERCULOUS MYCOBACTERIAL LUNG INFECTIONS.
CA2963085C (en) 2014-10-07 2023-02-21 Lam Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
MA40910A (en) 2014-11-07 2017-09-12 Civitas Therapeutics Inc RAPAMYCIN POWDERS FOR PULMONARY ADMINISTRATION
WO2016130645A1 (en) 2015-02-10 2016-08-18 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
JP6758325B2 (en) 2015-06-04 2020-09-23 クリティテック・インコーポレイテッド Taxane particles and their use
TWI678213B (en) 2015-07-22 2019-12-01 美商史倍壯製藥公司 A ready-to-use formulation for vincristine sulfate liposome injection
ES3067417T3 (en) 2015-08-11 2026-05-21 Cognoa Inc Apparatus to determine developmental progress with artificial intelligence and user input
US11972336B2 (en) 2015-12-18 2024-04-30 Cognoa, Inc. Machine learning platform and system for data analysis
CN114767860A (en) 2016-04-04 2022-07-22 克里蒂泰克公司 solid tumor therapy
CN118609834A (en) 2016-11-14 2024-09-06 科格诺亚公司 Methods and apparatus for assessing developmental status and providing coverage and reliability control
US10874768B2 (en) * 2017-01-20 2020-12-29 Covidien Lp Drug eluting medical device
JP7324709B2 (en) * 2017-02-09 2023-08-10 コグノア，インク． Platforms and systems for digital personalized medicine
US20220254461A1 (en) * 2017-02-09 2022-08-11 Cognoa, Inc. Machine learning algorithms for data analysis and classification
CA3063420A1 (en) 2017-06-09 2018-12-13 Crititech, Inc. Treatment of epithelial cysts by intracystic injection of antineoplastic particles
AU2018284247B2 (en) * 2017-06-14 2020-04-30 Crititech Inc. Methods for treating lung disorders
US10894019B2 (en) 2017-08-15 2021-01-19 University Of South Carolina Drug delivery system and method for targeting cancer stem cells
CA3076919A1 (en) 2017-10-03 2019-04-11 Crititech, Inc. Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
MX2020007997A (en) 2018-02-02 2020-12-03 Alexza Pharmaceuticals Inc Electrical condensation aerosol device.
EP3773505B1 (en) 2018-03-30 2026-04-29 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
EP3787602A4 (en) 2018-05-02 2022-03-23 Insmed Incorporated METHODS OF MAKING LIPOSOMAL DRUG FORMULATIONS
CN113873935B (en) 2019-03-22 2024-11-22 科格诺亚公司 Personalized digital treatment methods and devices
US11672767B2 (en) 2019-05-13 2023-06-13 University Of South Carolina Enzymatically cleavable self-assembled nanoparticles for morphogen delivery
WO2021040673A1 (en) * 2019-08-26 2021-03-04 Alain Martin Methods for the treatment of chronic hypoxemia and inhibiting lung fibrosis in patients with pulmonary fibrosis with and without copd
CN111067879B (en) * 2020-01-20 2022-08-09 珠海瑞思普利医药科技有限公司 Anti-tumor composition powder inhalation and preparation method thereof
US20240120050A1 (en) * 2022-10-07 2024-04-11 Insight Direct Usa, Inc. Machine learning method for predicting a health outcome of a patient using video and audio analytics
US20260188467A1 (en) * 2024-12-27 2026-07-02 Center for Social Dynamics, LLC Parallel Processing Systems and Methods For Real-Time Multimodal Behavioral Classification Using Neural Networks With Dynamic Content Adaptation

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560774A (en) * 1982-11-17 1985-12-24 Arizona State University Macrocyclic lactones
US4975421A (en) * 1985-08-19 1990-12-04 Bioglucan, Lp. Soluble phosphorylated glucan: methods and compositions for wound healing
WO1993017665A1 (en) * 1992-03-06 1993-09-16 Sievers Robert E Methods and apparatus for drug delivery using supercritical solutions
WO1993021938A1 (en) * 1992-05-04 1993-11-11 Adria Laboratories Methods for treating cancer using high-dose epirubicin
US5268164A (en) * 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5283383A (en) * 1992-02-13 1994-02-01 The United States Of America As Represented By The Department Of Health And Human Services Antitumor compound, compositions and method of use
WO1994010175A1 (en) * 1992-10-23 1994-05-11 The United States Of America, As Represented By The Secretary Of Health And Human Services Topoisomerase ii inhibitors and therapeutic uses therefor
US5348946A (en) * 1991-02-28 1994-09-20 Biochem Immunosystems, Inc. Heteroanthracycline antitumor analogs
EP0645145A2 (en) * 1993-09-29 1995-03-29 Bristol-Myers Squibb Company Stabilized pharmaceutical composition and stabilizing solvent
US5438072A (en) * 1992-12-02 1995-08-01 Rhone-Poulenc Rorer S.A. Taxoid-based compositions
EP0709090A2 (en) * 1994-10-14 1996-05-01 Eli Lilly And Company Compositions for treating resistant tumors
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4246399A (en) 1977-03-21 1981-01-20 Interx Research Corporation Complexes of doxorubicin exhibiting enhanced stability
JPS5795920A (en) 1980-12-04 1982-06-15 Teijin Ltd Remedy for respiratory disease
US4649911A (en) 1983-09-08 1987-03-17 Baylor College Of Medicine Small particle aerosol generator for treatment of respiratory disease including the lungs
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
GB8426672D0 (en) 1984-10-22 1984-11-28 Erba Farmitalia Pharmaceutical compositions
GB8501015D0 (en) 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
ATE78158T1 (en) * 1985-05-22 1992-08-15 Liposome Technology Inc METHOD AND SYSTEM FOR INHALATION OF LIPOSOMES.
US5124317A (en) 1985-08-02 1992-06-23 Farmitalia Carlo Erba S.P.A. Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
GB8519452D0 (en) 1985-08-02 1985-09-11 Erba Farmitalia Injectable solutions
US5124318A (en) 1985-08-02 1992-06-23 Farmitalia Carlo Erba S.R.L. Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
US4739046A (en) 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US4826817A (en) 1986-02-07 1989-05-02 Brown Thomas E Amino acid and hydroxyamino acid transporter compounds for therapeutic applications, process and use
US5049388A (en) * 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US5616334A (en) 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
US5115971A (en) 1988-09-23 1992-05-26 Battelle Memorial Institute Nebulizer device
US5511726A (en) 1988-09-23 1996-04-30 Battelle Memorial Institute Nebulizer device
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5171737A (en) 1989-03-03 1992-12-15 The Liposome Company, Inc. Emulsions
JPH05501505A (en) 1989-04-28 1993-03-25 ライカー　ラボラトリーズ，インコーポレイティド dry powder inhaler
DK0506785T3 (en) 1989-12-20 2000-07-24 Autoimmune Inc Improved treatment of autoimmune diseases by aerosol administration of autoantigens
US5593970A (en) 1990-06-11 1997-01-14 Biochem Pharma Inc. Heterocyclic anthracycline analogs
IT1243390B (en) 1990-11-22 1994-06-10 Vectorpharma Int PHARMACEUTICAL COMPOSITIONS IN THE FORM OF PARTICLES SUITABLE FOR THE CONTROLLED RELEASE OF PHARMACOLOGICALLY ACTIVE SUBSTANCES AND PROCEDURE FOR THEIR PREPARATION.
JP3507486B2 (en) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド Intrapulmonary administration of granulocyte colony-stimulating factor
US5645988A (en) 1991-05-08 1997-07-08 The United States Of America As Represented By The Department Of Health And Human Services Methods of identifying drugs with selective effects against cancer cells
DE69209183T2 (en) 1991-06-18 1996-08-08 American Home Prod Use of rapamycin to treat adult T cell lymphoma / leukemia
US5681812A (en) 1991-12-10 1997-10-28 Rush Presbyterian-St. Luke's Medical Center Methods and compositions for reducing multidrug resistance
US5627270A (en) 1991-12-13 1997-05-06 Trustees Of Princeton University Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5607691A (en) 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5273965A (en) 1992-07-02 1993-12-28 Cambridge Biotech Corporation Methods for enhancing drug delivery with modified saponins
US5606037A (en) 1992-11-09 1997-02-25 Biochem Pharma Inc. Processes antineoplastic heteronaphthoquinones
CA2149150C (en) 1992-11-27 2000-08-01 David R. Carver Injectable taxol composition with improved stability
ES2129117T3 (en) 1992-12-09 1999-06-01 Boehringer Ingelheim Pharma DISSOLUTION FORMULATIONS IN THE FORM OF STABILIZED MEDICINAL SPRAY.
US5591737A (en) 1992-12-17 1997-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5594139A (en) 1993-01-29 1997-01-14 Agouron Pharmaceuticals, Inc. Processes for preparing antiproliferative garft-inhibiting compounds
US5665382A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5709202A (en) 1993-05-21 1998-01-20 Aradigm Corporation Intrapulmonary delivery of aerosolized formulations
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5612474A (en) 1994-06-30 1997-03-18 Eli Lilly And Company Acid labile immunoconjugate intermediates
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
US5531219A (en) * 1994-11-04 1996-07-02 Alliance Pharmaceutical Corp. Use of liquid fluorocarbons to facilitate pulmonary drug delivery
US5561122A (en) 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
JPH08301762A (en) * 1995-05-12 1996-11-19 Teijin Ltd Lung cancer treatment
US5875776A (en) * 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560774A (en) * 1982-11-17 1985-12-24 Arizona State University Macrocyclic lactones
US4975421A (en) * 1985-08-19 1990-12-04 Bioglucan, Lp. Soluble phosphorylated glucan: methods and compositions for wound healing
US5268164A (en) * 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5348946A (en) * 1991-02-28 1994-09-20 Biochem Immunosystems, Inc. Heteroanthracycline antitumor analogs
US5283383A (en) * 1992-02-13 1994-02-01 The United States Of America As Represented By The Department Of Health And Human Services Antitumor compound, compositions and method of use
WO1993017665A1 (en) * 1992-03-06 1993-09-16 Sievers Robert E Methods and apparatus for drug delivery using supercritical solutions
WO1993021938A1 (en) * 1992-05-04 1993-11-11 Adria Laboratories Methods for treating cancer using high-dose epirubicin
WO1994010175A1 (en) * 1992-10-23 1994-05-11 The United States Of America, As Represented By The Secretary Of Health And Human Services Topoisomerase ii inhibitors and therapeutic uses therefor
US5438072A (en) * 1992-12-02 1995-08-01 Rhone-Poulenc Rorer S.A. Taxoid-based compositions
EP0645145A2 (en) * 1993-09-29 1995-03-29 Bristol-Myers Squibb Company Stabilized pharmaceutical composition and stabilizing solvent
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
EP0709090A2 (en) * 1994-10-14 1996-05-01 Eli Lilly And Company Compositions for treating resistant tumors

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
A.KINOSHITA: "Investigation of cisplatin inhalation chemotherapy effects on mice after air passage implantation of FM3A mice", J.JPN.SOC. CANCER THER., vol. 28, no. 4, 1993, pages 705 - 715, XP002078723 *
C.LI ET AL.: "Synthesis and evaluation of PEG-paclitaxel conjugate as a water soluble pactitaxel prodrug", PROC ANNU MEET AM ASSOC CANCER RES, vol. 37, 1996, pages 376, XP002094516 *
CRAIG LEWIS: "A review of the use of chemoprotectants in cancer chemotherapy", DRUG SAFETY, vol. 11, no. 3, 1994, pages 153 - 162, XP002094514 *
Database Cancerlit accession no. 71800442 & Ochanomizu Med. J., 18(3), p.103-114, 1970 *
G.T.BUDD ET AL.: "Clinical effects of amifostine (Ethyol) in patients treated with carboplatin", EUR J CANCER, vol. 32A, no. suppl. 4, 1996, pages S43 - S45, XP002094515 *
Medline Database Accession no. 83269156 *
S.OKUYUMA ET AL.: "Reinforcing aerosol cisplatin for radiotherapy of laryngeal cancer", TOHOKU J EXP MED, vol. 169, no. 3, 1993, pages 253 - 255, XP002094449 *
SHEVCHENKO ET AL.: "Inhalation of chemical substances and oxygen in radiotherapy of bronchial cancer", NEOPLASMA, vol. 15, no. 4, 1968, pages 419 - 426, XP002078721 *
T.TATSAMURA ET AL.: "Further study of nebulisation chemotherapy, a new chemotherapeutic method in the treatment of lung carcinomas: fundamental and clinical", BR.J.CANCER, vol. 68, no. 6, 1993, pages 1146 - 1149, XP002094448 *
T.TATSAMURA ET AL.: "New chemotherapeutic method for the treatment of tracheal and bronchial cancers--nebulization chemotherapy", GAN NO RINSHO, vol. 29, no. 7, 1983, pages 765 - 770 *
TATSUMURA ET AL.: "Further evaluation of the efficacy of nebulization chemotherapy in the treatment of lung cancer", CHEST, vol. 106, no. 2 suppl., 1994, pages 70s, XP002078722 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US9440034B2 (en) 2001-05-24 2016-09-13 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US9211382B2 (en) 2001-05-24 2015-12-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US9308208B2 (en) 2001-06-05 2016-04-12 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US8955512B2 (en) 2001-06-05 2015-02-17 Alexza Pharmaceuticals, Inc. Method of forming an aerosol for inhalation delivery
US7537009B2 (en) 2001-06-05 2009-05-26 Alexza Pharmaceuticals, Inc. Method of forming an aerosol for inhalation delivery
US9439907B2 (en) 2001-06-05 2016-09-13 Alexza Pharmaceutical, Inc. Method of forming an aerosol for inhalation delivery
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US8991387B2 (en) 2003-05-21 2015-03-31 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
US9370629B2 (en) 2003-05-21 2016-06-21 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US7581540B2 (en) 2004-08-12 2009-09-01 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages

Also Published As

Publication number Publication date
US20010038826A1 (en) 2001-11-08
DE69737510D1 (en) 2007-05-03
AU741439B2 (en) 2001-11-29
EP0954283A2 (en) 1999-11-10
ES2285743T3 (en) 2007-11-16
CA2628857C (en) 2011-09-13
US20010036444A1 (en) 2001-11-01
JP2001513078A (en) 2001-08-28
NZ336381A (en) 2000-11-24
ATE357214T1 (en) 2007-04-15
US6419901B2 (en) 2002-07-16
CA2275889A1 (en) 1998-07-09
WO1998029110A2 (en) 1998-07-09
AU7097598A (en) 1998-07-31
CA2628857A1 (en) 1998-07-09
BR9713661A (en) 2000-10-24
US20010038827A1 (en) 2001-11-08
CN1245423A (en) 2000-02-23
US6419900B2 (en) 2002-07-16
US6471943B1 (en) 2002-10-29
CA2275889C (en) 2008-03-18
EP0954283B1 (en) 2007-03-21
DE69737510T2 (en) 2007-12-06
US20020155066A1 (en) 2002-10-24
US6348209B2 (en) 2002-02-19

Similar Documents

Publication Publication Date Title
CA2275889A1 (en) Formulation and method for treating neoplasms by inhalation
WO2001066103A3 (en) Treatment of neoplasms by inhalation of carboplatin
CA2186260A1 (en) Composition comprising morphine, polypyrrolidone and a polyalkyleneoxide
CA2301057A1 (en) A method of administering liposomal encapsulated taxane
WO2002056912A3 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
AU1534699A (en) Osmotic dosage form comprising first and second coats
HUP9601884A3 (en) 6-(dimethylamino-methyl)-1-phenyl-cyclohexane compounds, their use as pharmaceutically active analgetic matarials and process for their preparation
AU3136897A (en) Compositions, methods and devices for the transdermal delivery of drugs
NZ504076A (en) A topical formulation which induces a minimal systemic effect when applied to the skin, the topical formulation comprising an immunosuppressive macrolide selected from sirolimus, FK506 and SDZ ASM 981 and a permeation modulator for the treatment of a dermatological condition
HUP9903377A3 (en) The mesylate salt of a macrocyclic bis-indolyl-maleimide derivative, process for its preparation, use thereof and pharmaceutical compositions containing the compound
CA2180535A1 (en) A method for treatment of psoriasis, by omeprazole or related compounds
CA2117891A1 (en) Method of treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and an s-phase or m-phase specific antineoplastic agent
WO1999022722A3 (en) Use of macrolides for the treatment of cancer and macular degeneration
WO1999063976A3 (en) Liver-selective glucocorticoid antagonist for treating diabetes
CA2157142A1 (en) Treatment of diseases caused by sebaceous gland disorders
WO1999033450A3 (en) Pharmaceutical composition containing sibutramine and orlistat
DE69200711D1 (en) Pharmaceutical compositions containing fluticasone propionate and oxikonazole or its salt for topical use.
AU2162700A (en) Supramolecular complexes containing therapeutic agents
NZ314488A (en) Anticancer medicaments containing alpha1-adrenoreceptor antagonist compounds
AU8851298A (en) L-threonate ferrous, as well as pharmaceutical composition and use for improvingand treating human anemia thereof
MX9709453A (en) Oral pharmaceutical composition of piperidinoalkanol compounds in solution form.
ZA969319B (en) Derivatives of imidazole n-benzyldioxole, their preparation process, their use as medicaments, pharmaceutical composition and new use.
AU1469097A (en) Pharmaceutical compounds
GR3035710T3 (en) Substituted benzenesulfonylureas and -thioureas, process for their preparation and the use of pharmaceutical preparations based on these compounds as well as medicaments containing them
ZA984832B (en) Pharmaceutical form for the administration of paclitaxel process for the preparation of a ready-to-use paclitaxel composition and use of this composition

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97181614.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 70975/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 336381

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2275889

Country of ref document: CA

Ref document number: 2275889

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/006122

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 1998 530358

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1997955033

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997955033

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 70975/98

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1997955033

Country of ref document: EP